Back

PRIORITY-AS: a novel score to predict adverse outcomes in patients with high-gradient aortic stenosis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Aetiologies, scores, and prediction models in heart failure Epidemiology, Prognosis, Outcome Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mariana Duarte Almeida

Hospital Center Tondela Viseu, Viseu (Portugal)

6 More presentations in this session

Presentation thumbnail
Exercise-induced oxygen desaturation identifies early post-discharge risk in patients with heart failure
Doctor I. Sunayama (Nishinomiya, JP)
Abstract Slides Video
Presentation thumbnail
Clinical profile and outcomes of infective endocarditis: real-world data from Kazakhstan
Doctor A. Togzhan (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Six-month event rates among patients with heart failure and those at risk: preliminary findings from the 'a year in the life of a heart failure patient ' prospective observational study
Doctor R. Doyle (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Epidemiological characteristics of patients with cardiomyopathy presenting with heart failure
Doctor E. Sener (Ankara, TR)
Abstract Slides Video
Presentation thumbnail
Identifying clinical instability in chronic heart failure: the role of microalbuminuria
Doctor P. Bernardes (Setubal, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Aetiologies, scores, and prediction models in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
PRIORiTize-TAVI might predict more than transcatheter aortic valve replacement waiting list priorities
thumbnail
Congress Presentation
Demographics and clinical outcomes of flow-gradient patterns of aortic stenosis: an analysis of the CURRENT AS Registry-2.
thumbnail
Congress Presentation
Development and validation of the ASGARD-S risk score for optimal timing of echocardiograms in asymptomatic patients with non-severe aortic valve stenosis: the SEAS and SALTIRE II trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources